Vista antibody is on a fast track to be developed as a checkpoint blockade agent by #kineta #kinetapharma in cancer. Very nice data showing reversal of negative immune signals similar to #PD1 Peomoter is responsive to hypoxia. Protein activated in low pH #immunotherapy #ASH22 #checkpoint